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Summary The relationship between oral contraceptives and breast cancer was evaluated among 2,022 cases
and 2,183 controls participating in a multicentre breast cancer screening programme. Ever use of oral
contraceptives was not related to breast cancer risk (RR= 1.0, 95% CI 0.9-1.2), and no overall patterns of
increasing or decreasing risks were observed according to the duration of use, or time since first or most
recent use. Although we had no women with extended periods of oral contraceptive use early in life, no
evidence of adverse effects attributable to short-term use before age 25, before first live birth or during the
perimenopausal period were observed. Further, oral contraceptives did not interact with other breast cancer
risk factors, except among those with a history of two or more breast biopsies (RR=2.0). Analyses by stage
of disease revealed that risk was related to the duration of oral contraceptive use: >5 years use was
associated with reduced risk for in situ cancer (RR=0.59) and increased risks for invasive cancers (RR= 1.5
and 1.4 respectively for small and large lesions). These data suggest that oral contraceptive effects may vary
by stage of disease, but provide no overall evidence of an association between oral contraceptives and breast
cancer.
The relationship between oral contraceptives and breast
cancer continues to receive widespread attention, particularly
given the substantial incidence of this disease and the high
prevalence of oral contraceptive use. Endogenous hormones
and reproductive factors have been implicated in the
aetiology of breast cancer (Kelsey & Hildreth, 1983;
Henderson et al., 1982), focusing concern on potential
adverse effects of exogenous hormones.
Epidemiological studies have consistently shown no overall
relationship between the use of oral contraceptives and the
risk of developing breast cancer (Trapido, 1981; Kay, 1981;
Kelsey et al., 1981; Brinton et al., 1982; CDC, 1983; Vessey
et al., 1983; Henneken et al., 1984; Rosenberg et al., 1984;
Sattin et al., 1986; LaVecchia et al., 1986; Lipnick et al.,
1986; Paul et al., 1986; Schlesselman et al., 1988), although
some investigators have reported risk elevations among
certain subgroups of exposed women. In particular, there is
evidence that oral contraceptives may alter the risk of breast
cancer in women with a family history of breast cancer
(Black et al., 1980; Brinton et al., 1982), women with prior
benign breast lesions (Fasal & Paffenbarger, 1975, 1977,
1980; Lees et al., 1978; Brinton et al., 1982; Janerich et al.,
1983), young women with extended periods of use before a
first live birth (Paffenbarger et al., 1977, 1980; Pike et al.,
1981; Harris et al., 1982; McPherson et al., 1983, 1987;
Meirik et al., 1986) or before age 25 (Pike et al., 1983;
Olsson et al., 1985; Meirik et al., 1986), women under 35
years of age at diagnosis (Kay & Hannaford, 1988) and
older women who used oral contraceptives around the
perimenopausal period (Vessey et al., 1979; Jick et al., 1980;
Paffenbarger et al., 1980; Kay, 1981; Brinton et al., 1982;
Henneken et al., 1984). These relationships, however, have
not been consistently found (Vessey et al., 1981, 1982; Stadel
et al., 1985; Miller et al., 1986; Prentice & Thomas, 1987;
Schlesselman et al., 1988).
Another important unanswered question is whether the
clinical stage of disease at breast cancer diagnosis varies
according to patterns of oral contraceptive use. Vessey et al.
(1979) found that users of oral contraceptives had less
advanced tumours at presentation than non-users, but it is
unclear whether this effect differed according to duration of
use. This inverse relationship between stage and oral
contraceptive use was interpreted initially as evidence for
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possible surveillance bias, e.g. oral contraceptive users, who
are more likely than non-users to be under medical
surveillance, may have their tumours diagnosed at an earlier
stage. After further analyses, the authors reported that the
observed inverse relationship may be attributed to oral
contraceptives exerting favourable effects on tumour growth
and spread (Vessey et al., 1983).
The present analysis was designed to address the
relationship between oral contraceptive use and breast cancer
risk in an expanded case-control study. Initial results from
this study, based on the first 4 years of a mammography
screening programme, were published in 1982 (Brinton et al.,
1982). Since that time, the study was expanded to include
cases identified through the final 3 years of the screening
programme. In addition, oral contraceptive effects were
evaluated according to the stage of disease at breast cancer
diagnosis.
Materials and methods
Study subjects were women enrolled in a nationwide breast
cancer screening programme, the Breast Cancer Detection
Demonstration Project (BCDDP), jointly sponsored by the
National Cancer Institute and the American Cancer Society.
Details of the study population and methodology have been
described elsewhere (Brinton et al., 1983, 1986a,b). Briefly,
participants in the BCDDP were recruited between 1973 and
1975, and followed through 1980 for a 5-year programme of
annual breast examinations. Cases for the present analysis
were all women who were diagnosed with breast cancer
during the screening period. The initial phase of the study
was conducted among women diagnosed with primary breast
cancer during July 1973 to May 1977. A 3-year extension of
the study included cases diagnosed through November 1980.
Control subjects were also women enrolled in the
screening programme, but who were not recommended for a
breast biopsy over the course of the project. Controls were
randomly chosen from a large pool of eligible women and
frequency-stratified to cancer cases on age (within 5 years),
race, screening centre, year of entry into the screening
programme and duration of participation in the project.
Uniformly trained study personnel conducted structured
home interviews for all study subjects. Information was
obtained on social and demographic factors, menstrual and
reproductive histories, family history of breast cancer,
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history of benign breast lesions, weight, height and use of
exogenous hormones. Women were asked whether they had
ever taken oral contraceptives or menopausal oestrogens. A
life-time monthly calendar was used to assist recall and
accurate recording of information on every pill used.
Respondents who answered affirmatively to using oral
contraceptives were then queried concerning specific para-
meters of exposure, and for each episode of use the times of
first and last use were recorded on the calendar. A photo-
graph book of oral contraceptive preparations was used to
aid in identifying the types of preparations and the dosages.
A woman was defined as an oral contraceptive user if she
had ever taken these preparations.
Of the 4,300 cases identified for study, 77.9% completed
personal interviews. The participation rate for the 4,317
controls selected was 83.0%. Major reasons for non-response
were refusals (5.0% cases, 7.7% controls), moved from the
study area (1.7% cases, 4.3% controls) and death (11.5%
cases, 2.3% controls).
The analysis excluded 134 cases and 38 controls who
reported a history of breast cancer before entering the
screening programme. In addition, we limited the study
group to white women (87% of the study population) and
those who were premenopausal or naturally menopausal.
Because women who undergo surgically induced menopause
have a lower risk of breast cancer and a higher probability
of being prescribed hormone replacement therapy, and
because of the difficulty in controlling for the effects of
exogenous hormone use, which was very prevalent in this
study population, we eliminated women who had an arti-
ficial menopause (842 cases, 954 controls).
Breast tumours were classified as in situ or invasive based
on a standardised reporting system. For invasive disease,
information from mastectomy specimens on tumour length,
width and depth was reviewed. Invasive lesions that were less
than or equal to 1 cm for each dimension were classified as
small invasive cancers, and all others as larger invasive
cancers. A total of 279 tumours were classified as in situ
cancer, 243 as small invasive cancer and 1,141 as larger
invasive cancer. No information on tumour dimensions was
available for 359 cases who were analysed separately.
Unconditional logistic regression (Breslow & Day, 1980)
was used to estimate relative risks (RR) and associated 95%
confidence intervals (CI). Oral contraceptive use was the
main exposure variable, and the effects of potential con-
founders were evaluated by entering variables one at a time
to the logistic model containing oral contraceptive use. If the
resulting risk estimate for oral contraceptive use changed by
more than 5%, subsequent risk estimates were adjusted for
the factor. A large number of variables, including reproduc-
tive factors (e.g. age at first live birth, number of live births),
menstrual factors, family history of breast cancer, indices of
body size and sociodemographic factors, were examined as
possible confounders. Age (at diagnosis for cases and a
comparable age for matched controls) and menopausal
status (pre- versus post-menopausal) were the only factors
that materially changed the risk estimates in this study
population and have been controlled in the analyses.
Table II Relative risks of breast cancer associated with selected
measures of oral contraceptive use, Breast Cancer Detection
Demonstration Project, 1973-1980
Number of Number of
Measure of use cases controls RRa 95% CI
Years of use
<1 177 205 0.93 0.7-1.2
2-4 90 123 0.79 0.6-1.1
5-9 126 108 1.24 0.9-1.6
10-14 58 59 1.01 0.7-1.5
. 15 8 13 0.65 0.3-1.6
Trend test 0.10 (P=0.93)
Years since first use
<5 25 40 0.66 0.4-1.1
5-9 112 121 0.99 0.8-1.3
10-14 225 222 1.08 0.9-1.3
. 15 98 127 0.82 0.6-1.1
Trend test -0.36 (P=0.72)
Years since last use
Current 47 57 0.81 0.5-1.2
1-3 93 96 1.01 0.7-1.4
4-6 102 109 1.02 0.8-1.4
.7 221 251 0.96 0.8-1.2
Trend test -0.25 (P=0.80)
'All risks are relative to women who never used oral
contraceptives (1,540 cases, 1,667 controls), and are adjusted for age
and menopausal status. Unknowns are excluded from the analysis.
Possible effect modification of the association between oral
contraceptives and breast cancer was also evaluated by
multivariate models (Breslow & Day, 1980). Statistical
significance (P<0.05) of possible interaction effects was
determined by computing the difference in log-likelihood
estimates between models excluding and including the inter-
action term. Two-tailed tests for trend in the logistic analyses
were obtained by treating categories of the exposure variable
as interval data. Because the study employed a matched
design, matched analyses were also undertaken (Lubin,
1981), and produced results similar to the unmatched
analyses chosen for presentation.
Results
Rates of oral contraceptive use among study subjects varied
by age, but none of the age-specific risk estimates were
significantly different from unity (Table T). Women 40-44
years of age had the highest risk estimate (RR= 1.4). The
overall age-adjusted relative risk estimate for the association
between ever use of oral contraceptives and breast cancer
was 1.0 (95% CI 0.9-1.2).
Table II presents relative risk estimates for breast cancer
according to selected measures of oral contraceptive use. No
consistent patterns of risk were observed for the total length
of time oral contraceptives were used, the time since first use
Table I Rates of oral contraceptive use among cases and controls by age at breast cancer
diagnosis, Breast Cancer Detection Demonstration Project, 1973-1980
Age at diagnosis Cases Controls Relative 95% confidence
(Years) No. % users No. % users riska interval
<40 76 71.1 92 71.7 1.01 0.5-1.9
40-44 208 56.7 235 49.8 1.36 0.9-1.9
45-49 385 38.4 377 36.9 1.07 0.8-1.4
50-54 425 23.8 448 27.7 0.82 0.6-1.1
55-59 331 14.5 366 15.0 0.99 0.6-1.5
60 597 2.2 665 2.3 1.02 0.5-2.2
Total 2,022 23.8 2,183 23.6 1.02 0.9-1.2
aRelative risks are adjusted for age. Unknowns are excluded from the analysis.ORAL CONTRACEPTIVES AND BREAST CANCER 377
or the time since last use. Neither short-term use (RR=0.85
for 1 year or less) nor long-term use (RR =0.65 for 15 years
or more) was related to increased risk for breast cancer.
Further analyses of the combined effects of duration and
latency or recency of use did not identify any groups at
particularly altered risk. (For example, women who used
oral contraceptives for 10 or more years and whose first use
occurred 10 or more years before diagnosis had a relative
risk estimate of 0.99.)
Several recent papers have suggested that any adverse
effects of oral contraceptives in relation to breast cancer may
be confined to younger women who used these preparations
for extended time periods at an early age or before a first
live birth (Jick et al., 1980; Pike et al., 1981; Harris et al.,
1982; Meirik et al., 1986; McPherson et al., 1987). We thus
attempted to examine these issues further. Because of the age
distribution of our subjects, we had no women who had used
oral contraceptives for extended periods -of time before age
25 (Table III). There was no evidence that oral contracep-
tives used for less than 5 years before age 25 were associated
with increased risk (RR=0.96, 95% CI 0.6-1.7). The risk of
breast cancer associated with use after age 25 was also not
elevated, with the exception of a slight increase in risk for
women who used oral contraceptives for 5-9 years
(RR= 1.4, 95% CI 1.0-1.8). A similar analysis of the
duration of oral contraceptive use before and after a first
live birth failed to demonstrate any significant relationships.
Another issue raised by previous studies is whether oral
contraceptive use during perimenopausal years changes a
women's risk for breast cancer (Vessey et al., 1979; Jick et
al., 1980; Kay, 1981; Brinton et al., 1982; Henneken et al.,
1984). Oral contraceptive use around the time of menopause
may extend a woman's menstrual cycles, resulting in
unusually high levels of circulating oestrogens and
progestogens when these hormones would normally be at
lower levels due to the onset of menopause. We estimated
risk according to the duration of oral contraceptive use in
premenopausal and post-menopausal women, focusing on
exposures before and after age 40 (Table IV). Only one of
the point estimates of risk was significant (RR=1.9 for 6-7
years of use before age 40 in premenopausal women), and no
clear patterns of risk by duration of use within age
categories were evident. The apparent increase in risk with
increasing duration of use before age 40 in premenopausal
women did not persist in the last category of use, and the
test for linear trend was not significant. Premenopausal
women who used oral contraceptives for 8 or more years
after age 40 did not experience any substantial elevation in
risk (RR= 1.1).
The effect of other breast cancer risk factors on the
relationship of oral contraceptive use to breast cancer risk
was also examined (Table V). Risks associated with oral
contraceptive use did not vary substantially according to
presence or absence of breast cancer in a first degree relative,
and there was no evidence of effect modification according
to whether the affected relative was a mother or sister(s).
Although based on small numbers, oral contraceptive use in
women with two or more previous breast biopsies was
associated with an elevation in risk (RR=2.0, 95% CI 0.97-
4.1). However, this potential interactive effect of oral
contraceptive use and a history of breast biopsy on the risk
of breast cancer was not statistically significant based on the
inclusion of an interaction term in the model. The
relationship between oral contraceptives and breast cancer
was not appreciably modified by the other risk variables
considered, including age at first live birth, use of
menopausal hormones, adiposity or weight (not shown).
Smoking and alcohol use also did not materially alter the
risk estimates for oral contraceptive use in relation to breast
cancer (not shown).
Table III Relative risks of breast cancer associated with ever use and years of use of
oral contraceptives before and after age 25, Breast Cancer Detection Demonstration
Project, 1973-1980
Number of Number of
Measure of use cases controls RRa 95% CI
Non-userb 1,540 1,667 1.00
Used before age 25 26 30 0.96 0.6-1.7
Used after age 25 455 504 0.98 0.8-1.2
Years of use before age 25
<5 26 30 0.96 0.6-1.7
Years of use after age 25
<5 2S0 345 0.88 0.7-1.1
5-9 122 99 1.37 1.0-1.8
>10 50 60 0.91 0.6-1.3
aRelative risks are adjusted for age. Unknowns are excluded from the analysis.
bReference category.
Table IV Relative riska of breast cancer associated with years of oral contraceptive use before and after the
age of 40, by menopause status, Breast Cancer Detection Demonstration Project, 1973-1980
Premenopausal Post-menopausal
Years of use within Use before Use after Use before Use after
age categories age 40 age 40 age 40 age 40
<2 0.94(124) 0.95(64) 0.72(21) 0.76(44)
2-3 1.21 (61) 1.46(33) 1.44 (8) 0.51 (11)
4-5 1.47 (42) 1.03(27) 1.01 (4) 0.97(12)
6-7 1.87 (33)b 1.18(18) 0.67 (1) 1.49(10)
.8 0.72 (31) 1.05(20) (0) 1.00(10)
Trend test 0.68(P=0.50) 0.66(P=0.51) -1.01 (P=0.30) -0.50(P=0.61)
aRisks relative to women who never used oral contraceptives in each respective menopausal group (517
cases, 506 controls premenopausal; 1,023 cases, 1,161 controls post-menopausal), adjusted for age. Numbers in
parentheses are number of exposed cases. Unknowns are excluded from the analysis. Observations pertaining
to years of use before and after age 40 are not necessarily independent, i.e. women could be included in both
categories if use occurred before as well as after age 40. b95% CI excludes 1.0.378 J.L. STANFORD et al.
Because of the potential interaction between oral
contraceptives and prior benign disease, the temporal
relation of oral contraceptive use to breast biopsy was
considered (Table VI). An elevation in risk of breast cancer
for oral contraceptive users was mainly observed in women
who had used these preparations for less than 5 years before
their first breast biopsy (RR=1.5, 95% CI 0.8-2.7). No
increase in breast cancer risk was noted for use after the
initial breast biopsy. Similar risk estimates were obtained
when duration of use was categorised as <1 and > 1 year of
use before or after breast biopsy.
Further analyses assessed oral contraceptive effects
according to the stage of breast cancer at the time of
diagnosis. Ever use of oral contraceptives was not signifi-
cantly related to pathological stages of breast cancer (Table
VII); the relative risks for in situ, small invasive, large
invasive and unknown stage tumours were 0.83, 1.1, 1.1 and
0.78, respectively. Risk estimates for ever- compared to
never-use of oral contraceptives varied somewhat according
to lymph node involvement at the time of mastectomy:
RR=0.99 (95% CI 0.7-1.3) among women with no positive
lymph nodes, RR=1.2 (95% CI 0.6-2.2) for women with
one to three positive nodes, RR= 1.2 (95% CI 0.6-2.5) for
women with four or more positive nodes, and RR=0.76
(95% CI 0.4-1.5) for women with an unknown number of
involved nodes.
The duration of oral contraceptive use was also examined
for the different stages of disease. For in situ breast cancer,
risk was inversely related to the total length of time a
woman used oral contraceptives (RR=0.59, 95% CI 0.3-1.0
for _5 years use). This reduced risk of in situ cancer in
long-term users was present in both recent users (RR=0.56
for those with < 1 year since last use) and those whose last
use occurred more than 1 year before diagnosis (RR =0.60).
A similar pattern of lower risk in long-auration oral
contraceptive users was observed in women with unknown
stage of disease. In contrast, elevated risks were noted for
small (RR = 1.5) and large (RR= 1.4) invasive cancers in users
of 5 or more years duration.
Analyses of duration of use by number of involved lymph
Table V Relative risks of breast cancer associated with ever use of oral contraceptives
by selected risk factors, Breast Cancer Detection Demonstration Project, 1973-1980
Cases Controls
reporting reporting
Risk factor OC use OC use RRa 95% CI
Family history of breast cancer
Mother No 399 457 0.97 0.8-1.2
Yes 75 55 0.80 0.5-1.2
Sister(s)b No 260 296 1.10 0.9-1.4
Yes 42 13 1.21 0.6-2.5
History of breast biopsy
No 372 446 0.92 0.8-1.1
1 69 57 1.00 0.7-1.5
>2 39 13 1.99 0.97-4.1
Age at first live birth (years)
<20 35 50 0.74 0.4-1.2
20-24 191 238 0.93 0.2-1.2
25-29 154 135 1.09 0.8-1.4
30 62 46 1.04 0.7-1.6
Nulliparous 40 46 0.89 0.5-1.4
Menopausal hormone use (ever)
No 384 404 0.97 0.8-1.2
Yes 98 112 0.92 0.7-1.3
Adiposity indexc
21 81 82 0.80 0.5-1.3
22-23 147 153 0.89 0.6-1.2
24-25 122 125 0.94 0.7-1.3
26 32 43 0.88 0.5-1.5
aRelative risks are adjusted for age and menopausal status and represent ever
compared to never use of oral contraceptives within each risk factor category. Unknowns
are excluded from the analysis. bWomen with no sister(s) are excluded from analysis.
cWeight (kg)/height (c'2).
Table VI Relative risks of breast cancer associated with ever use and years of use of oral
contraceptives before and after breast biopsy, Breast Cancer Detection Demonstration Project,
1973-1980
Number of Number of
Measure of use cases controls RRa 95% CI
Non-userb 341 275 1.00
Used before breast biopsy 47 25 1.22 0.7-2.1
Used after breast biopsy 72 55 0.87 0.6-1.3
Years of use before breast biopsy
<5 41 18 1.48 0.8-2.7
> 5 6 7 0.55 0.2-1.7
Years of use after breast biopsy
< 5 47 35 0.91 0.5-1.5
, 5 25 20 0.80 0.4-1.5
aRelative risks are adjusted for age and menopausal status. Analysis limited to women with a
history of breast biopsy. Unknowns excluded from the analysis. bReference category.ORAL CONTRACEPTIVES AND BREAST CANCER 379
Table VII Relative riska of breast cancer associated with oral contraceptive use by stage
of disease, Breast Cancer Detection Demonstration Project, 1973-1980
Measure of use In situ Small invasive Large invasive Unknown stage
Ever use
Nob 1.00(213) 1.00(186) 1.00(858) 1.00(283)
Yes 0.83 (66) 1.10 (57) 1.05(283) 0.78 (76)
95% CI 0.6-1.1 0.8-1.6 0.9-1.3 0.6-1.1
Years of use
<5 0.96 (47) 0.86 (27) 0.87(142) 0.85 (51)
I>5 0.59 (17) 1.54 (27) 1.37c (126) 0.65 (22)
aRelative risks are adjusted for age and menopausal status. Unknowns are excluded
from the analysis. Numbers in parentheses represent the number of cases. bReference
category. C95% CI excludes 1.0.
Table VIII Relative risksa of in situ and invasive breast cancer
associated with oral contraceptive use by selected risk factors, Breast
Cancer Detection Demonstration Project, 1973-1980
Risk factor In situ Invasive
Family history of breast cancer
(first degree relative)
No 0.77(50) 1.09(262)
Yes 1.11 (16) 1.22 (75)
History of breast biopsy
No 0.69(40) 1.07(268)
1 1.39(19) 1.00 (43)
,, 2 1.38 (6) 2.43b(28)
Age at first live birth (years)
<25 0.97(38) 1.03(161)
25-29 0.79(16) 1.32(112)
30 0.65 (5) 1.18 (40)
Nulliparous 0.77 (7) 0.87 (27)
aRelative risks are adjusted for age and menopausal status and
represent ever compared to never use of oral contraceptives within
each risk factor category. Numbers in parentheses are numbers of
exposed cases. Unknowns are excluded from the analysis. b95% CI
excludes 1.0.
nodes revealed no significant associations in relation to
short-term (<5 years) use, or in relation to long-term (>5
years) use in women with no involved nodes (RR=1.0) or
an unknown number of involved nodes (RR=0.74). Non-
significant increases in risk were observed for users of 5 or
more years duration who had one to three positive nodes
(RR= 1.7) and those with four or more positive nodes
(RR= 1.9); these elevations in risk were further examined by
stratification on stage of disease. For long-term users with
one to three positive nodes, risk was higher in those with
small invasive (RR=3.1) compared to large invasive
(RR=1.5) tumours. Among women with four or more
positive nodes, risk in relation to long-term oral contracep-
tive use was higher in those with large invasive (RR= 1.8)
compared to small invasive (RR= 1.3) cancers.
Additional analyses examined oral contraceptive effects on
the risk of in situ and invasive cancer according to other risk
factors (Table VIII). There was no evidence that risks in
relation to oral contraceptive use differed for either in situ or
invasive cancers by a family history of breast cancer in a
first degree relative, or age at first live birth. Oral contracep-
tives did exert an adverse effect on the risk for invasive
cancer in women with two or more biopsies for benign
lesions (RR=2.4).
Discussion
The results of the present study, based on a population of
older women, provide further evidence against an association
between ever use of oral contraceptives and risk of breast
cancer. There were no overall elevations in risk according to
the duration of oral contraceptive use, or time intervals since
first or last use. Oral contraceptive effects also did not
interact with a family history of breast cancer, age at first
live birth, use of menopausal oestrogens or obesity. In
addition, oral contraceptive use before age 25, before a first
birth or during the perimenopausal period did not appear to
influence substantially the risk of breast cancer, although
there were too few exposed women in some subgroups to
assess risk adequately. However, risk estimates for breast
cancer in relation to oral contraceptive use did vary
according to previous biopsies for benign breast disease and
stage of breast cancer at the time of diagnosis.
Previous reports of an adverse effect of oral contraceptives
in young women with extended durations of use before age
25 or a first live birth (Paffenbarger, 1977; Pike et al., 1981,
1983; Harris et al., 1982; McPherson et al., 1983, 1987;
Olsson et al., 1985; Meirik et al., 1986) prompted us to
examine this issue. Since no women in the present study had
used oral contraceptives for extended periods of time at an
early age, we were unable to estimate risks in relation to
such use. However, based on small numbers, oral contracep-
tive use lasting less than 5 years before age 25 or first birth
was not associated with risk.
In contrast to earlier reports (Vessey et al., 1979; Jick et
al., 1980; Paffenbarger et al., 1980; Brinton et al., 1982;
Henneken et al., 1984), we found no evidence that oral
contraceptive use around the time of menopause increased
the risk of breast cancer. Premenopausal women who took
oral contraceptives for extended periods of time after age 40
were not found to be at high risk. Use of oral contraceptives
during the perimenopause might be expected to enhance the
risk of breast cancer by prolonging menstrual cycling, main-
taining higher levels of oestrogens and progestogens at a
time when these hormones would be circulating at lower
levels due to changes in ovarian function associated with the
menopause.
It is noteworthy that we found no evidence of significant
effect modification of oral contraceptives by other breast
cancer risk factors. These results fail to confirm earlier
studies that found certain high-risk groups of users, specifi-
cally those with a family history of breast cancer (Black et
al., 1980; Brinton et al., 1982). An earlier report based on a
subset of this study population showed elevated risks for
users of oral contraceptives who had a positive history of
breast cancer in a sister(s) (Brinton et al., 1982). This
discrepancy with the present results may be due to the
smaller numbers of exposed women included in the initial
report, and to the decision to limit this analysis of sister(s)
with breast cancer to women who reported having at least
one sister.
We did observe elevations in risk among oral contracep-
tive users with two or more previous biopsies for benign
breast lesions. Within the context of the BCDDP, women
with two or more breast biopsies are thought to represent
the group that is more similar to benign breast disease
defined in other studies. In an earlier publication based on
participants of the BCDDP, Brinton et al. (1979) noted the380 J.L. STANFORD et al.
high prevalence of breast biopsy in this screening population
and that a previous history of one biopsy was not a risk
factor for breast cancer (RR=0.83), whereas a history of
more than one biopsy was associated with an increased risk
(RR=2.1). These present findings are somewhat surprising
since oral contraceptives protect against benign breast
disease. It is possible that the benign lesions arising in the
context of exposure to oral contraceptives which protect
against such lesions represent unusual types that are more
strongly related to breast cancer risk.
The relationship between oral contraceptive use and the
stage of breast cancer at the time of diagnosis was of
primary interest in the present study. Previous studies
reported less advanced disease in users, and ascribed the
finding to either surveillance bias from early detection of
tumours in women taking oral contraceptives or favourable
biological effects of oral contraceptives on tumour growth
(Vessey et al., 1979, 1983; Ravnihar et al., 1988). Skegg
(1988) recently reviewed the potential influence of
surveillance bias on results of studies of breast cancer in
relation to oral contraceptives, and noted that such bias
could produce a spuriously elevated risk. This would be
particularly true if oral contraceptive users more frequently
practice breast self-examination or have more routine
screening by medical personnel (palpation and mammo-
graphy), resulting in the identification of the breast cancer at
an earlier stage.
In addition to the potential influence of surveillance bias,
there is some suggestion that oral contraceptives may exert
favourable biological activities on tumour growth and
spread. Studies of prognosis reported an apparent survival
advantage in breast cancer patients with a history of oral
contraceptive use (Spencer et al., 1978; Vessey et al., 1979;
Matthews et al., 1981; Rosner & Lane, 1986), although
adjustment for the stage of disease at diagnosis reduced the
beneficial effect in two studies (Vessey et al., 1979; Rosner &
Lane, 1986). A third study of oral contraceptives and
survival in breast cancer patients failed to support the notion
that oral contraceptives confer a positive influence on breast
tumour growth (Millard et al., 1987). Further, data from a
recent cohort study showed similar 5-year survival rates in
oral contraceptive users and controls (Kay & Hannaford,
1988).
Our findings contrast with prior reports (Vessey et al.,
1979, 1981; Ravnihar et al., 1988) that noted a higher
proportion of oral contraceptive users in women with early
stage disease. Although no significant relationships were
observed between ever use of oral contraceptives and the
clinical stage of disease at diagnosis, dissimilar risk patterns
were noted for users of 5 or more years duration among
women with in situ compared to invasive disease. In the
present study, oral contraceptive use was associated with a
reduction in risk for in situ disease in both recent users and
those who discontinued use > 1 year before diagnosis, but a
40-50% increase in risk for invasive cancer. Since all women
included in the present study were identified through a
breast cancer screening programme, it is less likely that our
results can be explained by surveillance bias. In fact, the
lower risk estimates observed for in situ breast cancer in
relation to oral contraceptive use argue against an 'early
detection' bias (Skegg, 1988). The results of this study must
await confirmation, but suggest that oral contraceptive
effects may vary by stage of disease. However, since results
based on subgroup analyses may be due .to chance alone,
these findings should be interpreted cautiously.
Few prior studies have analysed breast cancer risk factors
according to stage of disease. Brinton et al. (1983) found
generally similar risk factor profiles for women with benign
breast disease and those with in situ breast cancer; however,
different predictors of risk were observed for in situ
compared to invasive disease. Our findings regarding oral
contraceptive effects by pathological stage of disease support
the notion that in situ and invasive tumours may as groups
be aetiologically dissimilar.
In summary, our results provide further evidence against a
causal relationship between ever use of oral contraceptives
and breast cancer. Women with several prior biopsied benign
breast lesions who use oral contraceptives, however, may
experience some elevation in risk. The finding that oral
contraceptive use of 5 or more years duration is associated
with reduced risk for in situ disease, but increased risk for
invasive cancer must await confirmation. Based on these
results, additional studies of oral contraceptives in relation
to the stage of breast cancer at the time of diagnosis are
needed. Such future studies should account for possible
sources of surveillance bias that may inflitence investigations
of oral contraceptives and breast cancer.
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